249 related articles for article (PubMed ID: 23188545)
21. Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
Cienfuegos JA; Rotellar F; Baixauli J; Beorlegui C; Sola JJ; Arbea L; Pastor C; Arredondo J; Hernández-Lizoáin JL
Ann Surg Oncol; 2015 Mar; 22(3):916-23. PubMed ID: 25190129
[TBL] [Abstract][Full Text] [Related]
22. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer.
Vecchio FM; Valentini V; Minsky BD; Padula GD; Venkatraman ES; Balducci M; Miccichè F; Ricci R; Morganti AG; Gambacorta MA; Maurizi F; Coco C
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):752-60. PubMed ID: 15936556
[TBL] [Abstract][Full Text] [Related]
23. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?
Habr-Gama A; Sabbaga J; Gama-Rodrigues J; São Julião GP; Proscurshim I; Bailão Aguilar P; Nadalin W; Perez RO
Dis Colon Rectum; 2013 Oct; 56(10):1109-17. PubMed ID: 24022527
[TBL] [Abstract][Full Text] [Related]
24. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01).
Yeo SG; Kim DY; Kim TH; Chang HJ; Oh JH; Park W; Choi DH; Nam H; Kim JS; Cho MJ; Kim JH; Park JH; Kang MK; Koom WS; Kim JS; Nam TK; Chie EK; Kim JS; Lee KJ
Ann Surg; 2010 Dec; 252(6):998-1004. PubMed ID: 21107110
[TBL] [Abstract][Full Text] [Related]
25. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer.
Qiu HZ; Wu B; Xiao Y; Lin GL
Colorectal Dis; 2011 Dec; 13(12):1353-60. PubMed ID: 21689282
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
De Stefano A; Moretto R; Bucci L; Pepe S; Romano FJ; Cella AC; Attademo L; Rosanova M; De Falco S; Fiore G; Raimondo L; De Placido S; Carlomagno C
Clin Colorectal Cancer; 2014 Sep; 13(3):185-91. PubMed ID: 25080847
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.
Belluco C; Forlin M; Olivieri M; Cannizzaro R; Canzonieri V; Buonadonna A; Bidoli E; Matrone F; Bertola G; De Paoli A
Ann Surg Oncol; 2016 Dec; 23(13):4302-4309. PubMed ID: 27489059
[TBL] [Abstract][Full Text] [Related]
28. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.
Park IJ; You YN; Skibber JM; Rodriguez-Bigas MA; Feig B; Nguyen S; Hu CY; Chang GJ
Dis Colon Rectum; 2013 Feb; 56(2):135-41. PubMed ID: 23303140
[TBL] [Abstract][Full Text] [Related]
29. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
[TBL] [Abstract][Full Text] [Related]
30. Lymph node metastases in rectal cancer after preoperative radiochemotherapy: impact of intramesorectal distribution and residual micrometastatic involvement.
Sprenger T; Rothe H; Becker H; Beissbarth T; Homayounfar K; Gauss K; Kitz J; Wolff H; Scheel AH; Ghadimi M; Rödel C; Conradi LC; Liersch T
Am J Surg Pathol; 2013 Aug; 37(8):1283-9. PubMed ID: 23851331
[TBL] [Abstract][Full Text] [Related]
31. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
32. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
Lindebjerg J; Spindler KL; Ploen J; Jakobsen A
Colorectal Dis; 2009 Mar; 11(3):264-9. PubMed ID: 18573119
[TBL] [Abstract][Full Text] [Related]
33. Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.
Tsutsumi S; Tabe Y; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Shioya M; Saito J; Asao T; Nakano T; Kuwano H
Anticancer Res; 2011 Nov; 31(11):3963-7. PubMed ID: 22110227
[TBL] [Abstract][Full Text] [Related]
34. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results.
Lambrecht M; Vandecaveye V; De Keyzer F; Roels S; Penninckx F; Van Cutsem E; Filip C; Haustermans K
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):863-70. PubMed ID: 21398048
[TBL] [Abstract][Full Text] [Related]
35. Poorer Oncologic Outcome of Good Responders to PCRT With Remnant Lymph Nodes Defies the Oncologic Paradox in Patients With Rectal Cancer.
Cho E; Park IJ; Hong SM; Lee JL; Kim CW; Yoon YS; Lim SB; Yu CS; Kim JC
Clin Colorectal Cancer; 2019 Jun; 18(2):e171-e178. PubMed ID: 31027968
[TBL] [Abstract][Full Text] [Related]
36. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
37. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
38. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
[TBL] [Abstract][Full Text] [Related]
39. Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think!
de Campos-Lobato LF; Stocchi L; de Sousa JB; Buta M; Lavery IC; Fazio VW; Dietz DW; Kalady MF
Ann Surg Oncol; 2013 Oct; 20(11):3398-406. PubMed ID: 23812804
[TBL] [Abstract][Full Text] [Related]
40. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ
Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
